Compare JPMorgan Chase & Co (JPM) vs Stryker Corporation (SYK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs Stryker Corporation — how do they compare? JPMorgan Chase & Co trades at $332.99 (market cap $880.98B), while Stryker Corporation trades at $277.33 (market cap $106.24B). The key difference: JPMorgan Chase & Co is far larger — about 8.3× Stryker Corporation's market cap, and JPMorgan Chase & Co pays the higher dividend (1.99%). Which is the better fit depends on your goals — on Pluang, investors hold JPMorgan Chase & Co for 127 Days and Stryker Corporation for 21 Days on average.
| JPM | SYK | |
|---|---|---|
Market Cap | $880.98B | $106.24B |
Volume | 7,721,661 | 2,982,001 |
Sector | Financials | Health |
52-Week High | $365.18 | $388.35 |
52-Week Low | $282.84 | $269.75 |
Typical Hold Time | 127 Days | 21 Days |
Enterprise Value | $1.82T | $117.70B |
Dividend Yield | 1.99% | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase & Co. (JPM) trades at $331.42, up 0.56% today, with a bearish technical signal but strong fundamentals. Recent earnings beat expectations in Q1 and Q2 2026, with revenue growing to $181.85B in 2025. The stock shows a P/E of 14.2 and ROE of 18.43%, supported by a 'Moderate Buy' analyst consensus and a $373.18 price target.
Outlook remains positive due to robust profitability and institutional confidence, though risks include geopolitical tensions and cybersecurity threats highlighted in recent news. The stock offers value with upside potential, but investors should monitor cash flow trends and macroeconomic headwinds.
Stryker (SYK) trades at $277.33, up 0.7% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key support at $274 and resistance at $279, while fundamentals remain solid with a 14.43% net income margin and strong analyst consensus. Recent news highlights ongoing legal scrutiny related to a manufacturing issue disclosed in September 2026, which caused an 8.8% stock drop, but the company continues to innovate with product launches like Prophecy surgical planning.
The outlook for SYK is cautiously optimistic, with a consensus price target of $368.11 implying significant upside. Investment opportunities include robust profitability and growth in medical technology, but risks persist from legal investigations and potential operational disruptions. Investors should weigh strong analyst support against near-term sentiment headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About Stryker Corporation
Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →
